A controlled study of intravenous immunoglobulin in demyelinating neuropathy with IgM gammopathy

Annals of Neurology

Volumn 40, Issue 5, 1996, Pages 792-795

  Dalakas, Marinos C ^a   Quarles, Richard H ^b   Farrer, Robert G ^b   Dambrosia, James ^b   Soueidan, Shawke ^b   Stein, Daniel P ^b   Cupler, Edward ^b   Sekul, Elizabeth A ^b   Otero, Carlos ^b  

^a NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN G; PLACEBO;

ADULT; ANTIBODY TITER; ANTIGEN ANTIBODY COMPLEX; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMYELINATING NEUROPATHY; DEMYELINATION; DISEASE ASSOCIATION; DISEASE SEVERITY; GAMMOPATHY; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; INTRAVENOUS DRUG ADMINISTRATION; MUSCLE STRENGTH; PARAPROTEINEMIA; POLYNEUROPATHY; PRIORITY JOURNAL;

EID: 0029852729     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/ana.410400516     Document Type: Article

References (19)

1. Dalakas MC, Engel WK. Polyneuropathy with monoclonal gammopathy. Studies of 11 patients. Ann Neurol 1981;10:45-52
2. Latov N. Pathogenesis and therapy of neuropathies associated with monoclonal gammopathies. Ann Neurol 1995;37(suppl 1):S32-S42
3. Ilyas A, Quarles RH, MacIntosh TD, et al. IgM paraproteins associated with peripheral neuropathy bind to a ganglioside and to oligosaccharide moieties of the myclin-associated glycoprotein. Proc Natl Acad Sci USA 1984;81:1225-1229
4. Smith IS, Kahn SN, Lacey BW, et al. Chronic demyelinating neuropathy associated with benign IgM paraproteinemia. Brain 1983;106:169-195
5. Dalakas MC. Chronic idiopathic ataxic neuropathy. Ann Neurol 1986;19:545-554
6. Cook D, Dalakas M, Galdi A, et al. High-dose intravenous immunoglobulin in the treatment of demyelinating neuropathy associated with monoclonal gammopathy. Neurology 1990;40: 212-214
7. Dalakas MC, Illa I, Dambrosia JM, et al. A controlled trial of high-dose intravenous immunoglobulin infusions as treatment for dermatomyositis. N Engl J Med 1993;329:1993-2000
8. Dyck PJ, Kratz KM, Lehman KA, et al. The Rochestet diabetic neuropathy study: design criteria for types of neuropathy, selection bias, and reproducibility of neuropathic tests. Neurology 1991;41:799-807
9. Hills M, Armitage P. The two-period cross-over clinical trial. Br J Pharmacol. 1979;8:7-20
10. Quarles RH. Human monoclonal antibodies associated with neuropathy. Methods Enzymol 1989;179:291-299
11. Dalakas MC. High-dose intravenous immunoglobulin and serum viscosity: risk of precipitating thromboembolic events. Neurology 1994;44:223-226
12. Sekul EA, Cupler EJ, Dalakas MC. Aseptic meningitis associated with high-dose intravenous immunoglobulin therapy: frequency and risk factors. Ann Intern Med 1994;121:259-262
13. Leger JM, Younes-Chennoufi AB, Chassandro B, et al. Human immunoglobulin treatment of multifocal motor neuropathy and polyneuropathy associated with monoclonal gammopathy. J Neurol Neurosurg Psychiatry 1994;57(suppl): 46-49
14. Dalakas MC, Quarles RH. Autoimmune ataxic neuropathies (sensory ganglionopathies): are glycolipids the responsible autoantigens? Ann Neurol 1996;39:419-422
15. Kazatchkine MD, Dietrich G, Hurez V, et al. V region-mediated selection of autoreactive repertoires by intravenous immunoglobulin. Immunol Rev 1994;139:79-107
16. 5 subpopulation. J Neuroimmunol 1991;51:83-88
17. Vassilev T, Gelin C, Kaver SV, et al. Antibodies to the CD5 molecule in normal human immunoglobulin for therapeutic use. Clin Exp Immunol 1993;92:369-372
18. Basta M, Dalakas MC. High-dose intravenous immunoglobulin exerts its beneficial effect in patients with dermatomyositis by blocking endomysial deposition of activated complement fragments. J Clin Invest 1994;94:1729-1735
19. Monaco S, Bonetti B, Ferrari S, et al. Complement-dependent demyelination in patients with IgM monoclonal gammopathy and polyneuropathy. N Engl J Med 1990;322:844-852